117 KENDRICK STREET, NEEDHAM, MA
Candel Therapeutics Elects Four Directors at Annual Meeting
News, Material Contracts
Investor Presentation
Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Annual Report to Security Holders
Financial Results, Press Release
Announces Pricing of Public Offering
Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload